Hard to Treat Diseases Incorporated –
HTTD – Announces: Letter to the Shareholders
Delray Beach, Fla., October 6, 2005 – Hard to Treat Diseases Incorporated (HTTD) (Pink Sheets: HTDS)
A Letter from Hard to Treat Diseases, Incorporated
This letter is an opportunity to address the current status of the Company. Topics of concern and areas of importance are addressed below.
LITIGATION UPDATE:
The Federal Court issued its Memorandum Opinion on July 8, 2005. The Company’s attorneys have filed a Notice of Appeal and briefs will be posted on the Company’s website as soon as they are available. The Company does not feel the opinion reflects the evidence presented at trial.
In Oklahoma court, Shinn Capital Group, Inc. is attempting to obtain the Company’s Tubercin samples, test reports, studies, lab notes, and protocols regarding studies related to Tubercin. The Tubercin that the Company possesses is an asset of the Company. The test results and data are a result of agreements entered into by the Company and paid for by the Company. These assets belong to the Company and Shinn Capital Group, Inc. has no right to any of them.
TUBERCIN:
The Company has been in contact with Dr. Chung in South Korea. Mr. King was invited by Dr. Chung to meet with him with Ronald Shinn present. The meeting was to take place during the month of September, but as of yet no date has been set. Mr. King’s intentions are to present Dr. Chung with the extensive testing results done on Tubercin and the Company’s potential of moving his drug forward.
PROVISIONAL PATENT APPLICATION:
The Company’s application for the treatment of viral infections is a result of testing performed on a substance from Japan which the company possesses. The Company has been negotiating with a major drug firm in order to move the substance forward. The name of the substance and the drug firm will remain confidential until further negotiations are finalized.
RECYCLING PATENTS:
The Company owns 20% of International Foam Solutions, Inc., a Nevada corporation. The Company has recently discovered that the recycling patents in the names of Harvey Katz and Claudia Iovino are to be assigned to HTTD per employment agreements, SEC filings and USPTO (US Patent and Trademark Office) applications. Numerous attempts have been made to have the patents assigned to the Company. HTTD has formally notified the USPTO of the facts. In addition, the Company is in the process of formally notifying all parties that Katz has been attempting to do business with.
SECURITIES AND EXCHANGE COMMISSION (SEC):
Mr. King initiated a meeting with the enforcement division of the SEC in an attempt to protect the HTTD shareholders and investors. The Federal judge ruled that Ronald Shinn and Gerry Knight misled investors. Ronald Shinn issued 135 million shares of HTTD stock to Harvey Katz and his associates. It is believed by the Company that these shares were fraudulently issued and converted to free trading shares based on misrepresentations and fraudulent documents supplied by Harvey Katz. In addition to court documents, Mr. King has supplied the SEC with additional information and documents supporting the securities fraud.
Mr. King is in the process of supplying the SEC with all documents supporting the claim that the recycling patents are to be assigned to HTTD for the benefit of the shareholders.
CONCLUSION:
HTTD will continue to protect the interests of its shareholders by attempting to secure the rights to Tubercin, continuing the advancement of the Provisional Patent, finalizing a deal with a major drug firm and exploring the best option for our recycling division. Shareholders will be updated as developments occur.
Feel free to contact me if you have any questions or concerns.
Colm J. King, CEO
Hard to Treat Diseases, Incorporated
(561) 278-7856
www.htdsotc.com
Cautionary Note Regarding Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release may contain or constitute forward-looking statements. These forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions of the Private Securities Litigation Act of 1995, Hard to Treat Diseases, Inc. provides the following cautionary statement identifying important factors which, among others, could cause the actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.
|
